Literature DB >> 22697063

A case series of a luteolin formulation (NeuroProtek®) in children with autism spectrum disorders.

T C Theoharides, S Asadi, S Panagiotidou.   

Abstract

There has been an impressive, little understood increase in cases of autism spectrum disorders (ASD). The lack of any distinctive pathogenetic mechanism has hampered the development of any effective treatments. Increasing evidence indicates oxidative stress, brain inflammation, gastrointestinal (GI) dysfunction and allergic symptoms may be present in ASD patients. The flavone luteolin has anti-oxidant, anti-flammatory, anti-allergy and neuroprotective properties. Given these findings, a dietary supplement was developed with a unique mixture of luteolin with the related flavonoids quercetin and rutin in a liposomal formulation of olive kernel oil (OKO), which increases their absorption. Results are presented for children with ASD (n=37, 4-14 years old) who had not obtained any benefit from multiple other regimens and who used this formulation for at least 4 months. GI and allergy symptoms improved in about 75 percent of children, eye contact and attention in 50 percent, social interaction in 25 percent and resumption of speech in about 10 percent. There were no adverse effects. Even though these results represent an uncontrolled open case series, they are encouraging because they suggest good tolerability and potential effectiveness.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22697063     DOI: 10.1177/039463201202500201

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  30 in total

Review 1.  Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders?

Authors:  Theoharis C Theoharides; Irene Tsilioni; Huali Ren
Journal:  Expert Rev Clin Immunol       Date:  2019-04-22       Impact factor: 4.473

2.  Reply to: "Palmitoylethanolamide: problems regarding micronization, ultra-micronization and additives" Inflammopharmacology DOI:10.1007/s10787-014-0202-3.

Authors:  Stephen D Skaper; Laura Facci; Mariella Fusco; Maria Federica Della Valle; Morena Zusso; Barbara Costa; Pietro Giusti
Journal:  Inflammopharmacology       Date:  2014-05-27       Impact factor: 4.473

3.  Co-Ultramicronized Palmitoylethanolamide/Luteolin Facilitates the Development of Differentiating and Undifferentiated Rat Oligodendrocyte Progenitor Cells.

Authors:  Stephen D Skaper; Massimo Barbierato; Laura Facci; Mila Borri; Gabriella Contarini; Morena Zusso; Pietro Giusti
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

4.  Beneficial Effects of Co-Ultramicronized Palmitoylethanolamide/Luteolin in a Mouse Model of Autism and in a Case Report of Autism.

Authors:  Bartolomeo Bertolino; Rosalia Crupi; Daniela Impellizzeri; Giuseppe Bruschetta; Marika Cordaro; Rosalba Siracusa; Emanuela Esposito; Salvatore Cuzzocrea
Journal:  CNS Neurosci Ther       Date:  2016-10-04       Impact factor: 5.243

Review 5.  The role of nutraceuticals in the management of autism.

Authors:  Abdulrahman S Alanazi
Journal:  Saudi Pharm J       Date:  2012-10-23       Impact factor: 4.330

6.  Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism.

Authors:  Arti B Patel; Irene Tsilioni; Susan E Leeman; Theoharis C Theoharides
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-23       Impact factor: 11.205

7.  Corticotropin-releasing hormone and extracellular mitochondria augment IgE-stimulated human mast-cell vascular endothelial growth factor release, which is inhibited by luteolin.

Authors:  Shahrzad Asadi; Theoharis C Theoharides
Journal:  J Neuroinflammation       Date:  2012-05-04       Impact factor: 8.322

Review 8.  Perinatal stress, brain inflammation and risk of autism-review and proposal.

Authors:  Asimenia Angelidou; Shahrzad Asadi; Konstantinos-Dionysios Alysandratos; Anna Karagkouni; Stella Kourembanas; Theoharis C Theoharides
Journal:  BMC Pediatr       Date:  2012-07-02       Impact factor: 2.125

Review 9.  Mast cells in meningiomas and brain inflammation.

Authors:  Stavros Polyzoidis; Triantafyllia Koletsa; Smaro Panagiotidou; Keyoumars Ashkan; Theoharis C Theoharides
Journal:  J Neuroinflammation       Date:  2015-09-17       Impact factor: 8.322

Review 10.  Focal brain inflammation and autism.

Authors:  Theoharis C Theoharides; Shahrzad Asadi; Arti B Patel
Journal:  J Neuroinflammation       Date:  2013-04-09       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.